Pfizer Total Liabilities and Share Holders Equity 2012-2026 | PFE
Pfizer total liabilities and share holders equity from 2012 to 2026. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
- Pfizer total liabilities and share holders equity for the quarter ending March 31, 2026 was $208.731B, a 4.9% decline year-over-year.
- Pfizer total liabilities and share holders equity for 2024 was $213.396B, a 5.79% decline from 2023.
- Pfizer total liabilities and share holders equity for 2023 was $226.501B, a 14.86% increase from 2022.
- Pfizer total liabilities and share holders equity for 2022 was $197.205B, a 8.67% increase from 2021.
|
Pfizer Annual Total Liabilities and Share Holders Equity (Millions of US $) |
|
|---|---|
| 2024 | $213,396 |
| 2023 | $226,501 |
| 2022 | $197,205 |
| 2021 | $181,476 |
| 2020 | $154,229 |
| 2019 | $167,594 |
| 2018 | $159,422 |
| 2017 | $171,797 |
| 2016 | $171,615 |
| 2015 | $167,381 |
| 2014 | $167,566 |
| 2013 | $172,101 |
| 2012 | $185,798 |
| 2011 | $188,002 |
|
Pfizer Quarterly Total Liabilities and Share Holders Equity (Millions of US $) |
|
|---|---|
| 2025-09-30 | $208,731 |
| 2025-06-30 | $206,095 |
| 2025-03-31 | $208,028 |
| 2024-12-31 | $213,396 |
| 2024-09-30 | $219,476 |
| 2024-06-30 | $216,193 |
| 2024-03-31 | $221,095 |
| 2023-12-31 | $226,501 |
| 2023-09-30 | $215,021 |
| 2023-06-30 | $220,168 |
| 2023-03-31 | $195,617 |
| 2022-12-31 | $197,205 |
| 2022-09-30 | $195,350 |
| 2022-06-30 | $195,290 |
| 2022-03-31 | $183,841 |
| 2021-12-31 | $181,476 |
| 2021-09-30 | $179,188 |
| 2021-06-30 | $169,920 |
| 2021-03-31 | $158,818 |
| 2020-12-31 | $154,229 |
| 2020-09-30 | $178,983 |
| 2020-06-30 | $177,934 |
| 2020-03-31 | $166,336 |
| 2019-12-31 | $167,594 |
| 2019-09-30 | $170,446 |
| 2019-06-30 | $156,199 |
| 2019-03-31 | $155,421 |
| 2018-12-31 | $159,422 |
| 2018-09-30 | $167,838 |
| 2018-06-30 | $164,980 |
| 2018-03-31 | $164,612 |
| 2017-12-31 | $171,797 |
| 2017-09-30 | $172,151 |
| 2017-06-30 | $168,558 |
| 2017-03-31 | $168,784 |
| 2016-12-31 | $171,615 |
| 2016-09-30 | $178,430 |
| 2016-06-30 | $170,658 |
| 2016-03-31 | $162,929 |
| 2015-12-31 | $167,381 |
| 2015-09-30 | $170,867 |
| 2015-06-30 | $160,878 |
| 2015-03-31 | $160,640 |
| 2014-12-31 | $167,566 |
| 2014-09-30 | $171,362 |
| 2014-06-30 | $172,612 |
| 2014-03-31 | $171,808 |
| 2013-12-31 | $172,101 |
| 2013-09-30 | $175,521 |
| 2013-06-30 | $179,335 |
| 2013-03-31 | $187,398 |
| 2012-12-31 | $185,798 |
| 2012-09-30 | $182,603 |
| 2012-06-30 | $182,842 |
| 2012-03-31 | $185,683 |
| 2011-12-31 | $188,002 |
| 2011-09-30 | $196,132 |
| 2011-06-30 | $195,899 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |